April 20, 2025
Intangible Assets

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Holdings, Inc. — 176 Patents Issued and Outstanding Reinforces NeOnc’s Competitive Position — CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position.

Read More
Operating Assets

Tilray Brands Reports Q3 Fiscal 2025 Financial Results

Tilray Brands, Inc. Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. Distribution of Hemp-Derived THC Drinks Across 10 States, Increases Project 420 Cost Savings Plan to $33

Read More
Intangible Assets

Kaiser Aluminum Corporation Announces First Quarter 2025 Earnings Release, Conference Call, and Change in Inventory Accounting Methodology

FRANKLIN, Tenn., April 02, 2025–(BUSINESS WIRE)–Kaiser Aluminum Corporation (NASDAQ: KALU) (“Kaiser” or the “Company”) today announced that it plans to release its first quarter 2025 financial and operating results on Wednesday, April 23, 2025, after the market closes. The Company will host its quarterly conference call on Thursday, April 24, 2025, at 10:00 a.m. Eastern

Read More
Intangible Assets

UniFirst Announces Financial Results for the Second Quarter of Fiscal 2025

The segment’s operating and Adjusted EBITDA margin increases were primarily due to lower merchandise and production costs as a percentage of revenues. These were partially offset by higher healthcare claims expense and selling and administrative costs as a percentage of revenues in the second quarter of fiscal 2025. Specialty Garments Revenues for the quarter were $44.4

Read More
Operating Assets

Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the United States

Project will add strong recurring revenue stream to current portfolio VANCOUVER, BC / ACCESS Newswire / April 1, 2025 / Revolve Renewable Power Corp. (TSXV:REVV)(OTCQB:REVVF) (“Revolve” or the “Company“), a North American owner, operator and developer of renewable energy projects, is pleased to announce that it has signed a binding offer (the “Binding Offer“) for

Read More
Operating Assets

Kontrol Technologies Announces Fourth Quarter and Fiscal Year 2024 Financial Results

TORONTO, March 31, 2025–(BUSINESS WIRE)–Kontrol Technologies Corp. (CBOE.CA:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol Technologies” or “Kontrol” or “Company”) announces its results for the three months and fiscal year ended December 31, 2024. A complete set of the Financial Statements and Management’s Discussion & Analysis have been filed on SEDAR (www.sedarplus.ca). Fourth Quarter and Fiscal Year 2024 Highlights

Read More
Operating Assets

Boston Omaha Corporation Announces Full Year 2024 Financial Results

During fiscal 2024, “Net Other Income (Expense)” included $29.1 million in other investment income mainly driven by a $17.0 million unrealized gain on the Sky Harbour warrants held by Boston Omaha, other investment income of $7.8 million primarily related to the sale of real estate properties and changes in the fair value of remaining assets

Read More
Operating Assets

Prairie Operating Co. Completes Transformative Acquisition from Bayswater

Prairie Operating Co. Pro-Forma Reserve Data Pro-Forma Reserve Data Reconciliation of Non-GAAP Measure Reconciliation of Non-GAAP Measure Expands footprint in DJ Basin to ~55,000 net acres and inventory life to ~10 years Increases average daily production by ~25,700 net BOEPD Immediately accretive and maintains strong balance sheet Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) —

Read More
Operating Assets

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

– Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 – – As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $165 million upfront and eligible proceeds from Biogen collaboration anticipated to

Read More
Operating Assets

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 BOULDER, Colo., Mar. 13, 2025

Read More